🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

11 recruiting trials

for Wet Age-related Macular Degeneration (wAMD)

Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD NCT06718816n/a1 site📍 Beijing Beijing Anlong Biopharmaceutical Co., Ltd. Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration NCT07630649Phase 212 sites📍 Phoenix📍 Bakersfield📍 Fullerton Adverum Biotechnologies, Inc. · Tests: Ixo-vec Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD) NCT07185841Phase 1, Phase 21 site📍 Beijing Fujian Haixi Pharmaceuticals Co., Ltd. · Tests: HX9428 tablet Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) NCT06952452Phase 34 sites📍 San Cristóbal de La Laguna📍 Barcelona📍 Barcelona Parc de Salut Mar · Tests: Bevacizumab, Ranibizumab Ophthalmic Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) NCT07482176Phase 379 sites📍 Mesa📍 Phoenix📍 Phoenix Adverum Biotechnologies, Inc. · Tests: Ixo-vec, Aflibercept A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD NCT06346600n/a10 sites📍 Boston📍 Katy📍 Norfolk Skyline Therapeutics · Tests: SKG0106 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration NCT05197270Phase 1, Phase 226 sites📍 Phoenix📍 Oxnard📍 Sacramento 4D Molecular Therapeutics · Tests: 4D-150 IVT, Aflibercept IVT Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration NCT07064759Phase 3126 sites📍 Scottsdale📍 Sun City📍 Tucson 4D Molecular Therapeutics · Tests: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL) Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration NCT06132035Phase 17 sites📍 Manchester📍 Deerfield Beach📍 Augusta Caregen Co. Ltd. · Tests: CG-P5 peptide, Placebo, Aflibercept Injection [Eylea] Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) NCT05986864Phase 1, Phase 29 sites📍 St. Petersburg📍 Boston📍 Katy Skyline Therapeutics (US) Inc. · Tests: SKG0106 A Long-term Follow up Study of EXG102-031 in Participants With wAMD NCT06859515n/a1 site📍 Beijing Guangzhou Jiayin Biotech Ltd · Tests: No intervention, only for observational studies
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy